Health & Biotech
Check out the latest news, insights and unique analysis brought to you by Stockhead's team of business journalists and industry experts on Nyrada.
RELATED STOCKHEAD STORIES
Health & Biotech
‘Tide is turning for the healthcare sector’ – ASX biotechs making strong gains in 2024 Part 2
Health & Biotech
‘Tide is turning for the healthcare sector’ – ASX biotechs making strong gains in 2024 Part 1
Health & Biotech
The next Neuren? Nyrada chases after two big markets – stroke and traumatic brain injury
Health & Biotech
ASX Health Winners February: Law of attrition applies but biotech is a long term game; Nyrada up 5x last month
News
Closing Bell: Real estate, tech, and gold stocks surge as ASX retreats from all-time high
News
ASX February winners: The best 50 stocks as a ‘super-heroic small cap’ soars 322%
News
Rise and Shine: Everything you need to know before the ASX opens
News
Closing Bell: Buyers ambush benchmark setting new benchmark
Health & Biotech
Check Up: Big week in world of biotech after these 2 Nasdaq stocks announce breakthroughs
News
Rise and Shine: Everything you need to know before the ASX opens
News
Closing Bell: ASX200 flat and earthbound as Nyrada CEO exclusively shares 3 reasons for stunning +420pc session
News
ASX Small Caps Lunch Wrap: ASX is flat for now but inflation is chill and lithium is spiffium again
News
Top 10 at 11: Which biotechs are up after positive study results and deals?
Health & Biotech
ASX Health Stocks: Neuren’s sales come in at top of guidance range, crushing short seller’s claims
News
In Case You Missed It: R&D refunds for drug developers and a major uranium merger
News
Closing Bell: The ASX is slightly higher, but not much cooler on Monday
News
